Evidence map›Paper›PMID 38874690›Full record

ArticleMolecular biology reports2024

Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma.

Yanguang Yang, Shenghao Li, Qing Peng, Yinglin Guo, Yuting Gao, Yi Gong, Junlan Lu, Yuman Zhang, Xinli Shi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanguang YangLaboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan, 030000, China.
Shenghao LiDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, China.
Qing PengDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, China.
Yinglin GuoDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, China.
Yuting GaoLaboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan, 030000, China.
Yi GongLaboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan, 030000, China.
Junlan LuLaboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan, 030000, China.
Yuman ZhangDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, China.
Xinli ShiLaboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan, 030000, China. sxlsunshine@sina.com.

Funding

High-levels Talents of Shanxi University of Chinese Medicine 2023RC03Key Laboratory Construction Project of Shanxi Province zyyyjs2024035Traditional Chinese Medicine Innovation Team of Shanxi Province zyytd2024021
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is experiencing a concerning rise in both incidence and mortality rates. Current therapeutic strategies are limited in their effectiveness, largely due to the complex causes of the disease and significant levels of drug resistance. Given the latest developments in human umbilical cord mesenchymal stem cells (hUC-MSCs) research, there is a debate over the continued use of stem cell transplantation for treating tumors. Consequently, this study seeks to explore the role of hUC-MSCs in the management of HCC. METHODS AND

resultsHUC-MSCs increased the number (10.75 ± 1.50) in the DEN/TCPOBOP-induced mice hepatoma model, compared with DMSO group (7.25 ± 1.71). Moreover, the liver index in hUC-MSCs group (0.21 ± 0.06) was greater than that in DMSO group (0.09 ± 0.01). Immunohistochemical (IHC) analysis revealed that while hUC-MSCs did not alter Foxp3 expression, they significantly stimulated Ki67 expression, indicative of increased tumor cellular proliferation. Additionally, immunofluorescence (IF) studies showed that hUC-MSCs increased CD8

conclusionsAccording to this study, hUC-MSCs promoted the growth of liver tumors. Therefore, we proposed that hUC-MSCs are not suitable for treating HCC, as they exhibit clinically prohibited abnormalities.

Indexed as

Carcinoma, HepatocellularCell ProliferationInterleukin-18Liver NeoplasmsMesenchymal Stem CellsUmbilical CordAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansMaleMesenchymal Stem Cell TransplantationMiceInterleukin-18CD8+T cellsHepatocellular carcinomaIL-18IL-1βMSCs

Identifiers

PMID38874690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.